Repurposing Pyramax for the Treatment of Ebola Virus Disease: Additivity of the Lysosomotropic Pyronaridine and Non-Lysosomotropic Artesunate
Lane, T. R.; Dyall, J.; Mercer, L.; Goodin, C.; Foil, D. H.; Zhou, H.; Postnikova, E.; Liang, J. Y.; Holbrook, M.; Madrid, P.; Ekins, S.
Show abstract
We have recently identified three molecules (tilorone, quinacrine and pyronaridine tetraphosphate) which all demonstrated efficacy in the mouse model of infection with mouse-adapted Ebola virus (EBOV) model of disease and had similar in vitro inhibition of an Ebola pseudovirus (VSV-EBOV-GP), suggesting they interfere with viral entry. Using a machine learning model to predict lysosomotropism these compounds were evaluated for their ability to inhibit via a lysosomotropic mechanism in vitro. We now demonstrate in vitro that pyronaridine tetraphosphate is an inhibitor of Lysotracker accumulation in lysosomes (IC50 = 0.56 M). Further, we evaluated synergy between pyronaridine and artesunate (Pyramax(R)), which are used in combination to treat malaria. Artesunate was not found to have lysosomotropic activity in vitro and the combination effect on EBOV inhibition was shown to be additive. Pyramax(R) may represent a unique example of the repurposing of a combination product for another disease.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS- S and MERS-S pseudotyped particles 95%
- Modulation of triple artemisinin-based combination therapy pharmacodynamics by Plasmodium falciparum genotype 95%
- Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay 92%
Similar papers in this journal
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 97%
- The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators 96%
- Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2 95%
Similar papers in this journal
- The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models 94%
- Identification of novel chemical scaffolds that inhibit the growth of Mycobacterium tuberculosis in macrophages 94%
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 93%
Similar papers in this journal
- Metal Coordinating Inhibitors of Rift Valley Fever virus Replication 95%
- Identification of Celastrol as a novel HIV-1 Latency Reversal Agent by an Image-Based Screen 94%
- High-content quantitative high-throughput screening identifies a cell cycle-associated signaling cascade that regulates a multienzyme metabolic assembly for glucose metabolism 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.